Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Hellmann

Showing results (21-30 of 56) with videos related to

Pageof 6
Sort By:
Archives of Biochemistry and Biophysics|October 1, 1989
Purification of homogeneity and amino acid sequence analysis of a receptor protein for interleukin 1A S Stern, Y C Pan, R S Hellmann, et al.
The Journal of Tropical Medicine and Hygiene|April 1, 1995
Single-dose ampicillin/sulbactam versus ceftriaxone as treatment for uncomplicated gonorrhoea in a Ugandan STD clinic population with a high prevalence of PPNG infectionN S Hellmann, P S Nsubuga, D J Baingana-Baingi, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|October 7, 2004
Effects of the G190A substitution of HIV reverse transcriptase on phenotypic susceptibility of patient isolates to delavirdineErik J Uhlmann, Pablo Tebas, Gregory A Storch, et al.
European Journal of Public Health|November 18, 2022
Labor force participation during COVID-19 and risk of depression: a Danish register studySophie S Hellmann, Sanne P Møller, Annette K Ersbøll, et al.
AIDS (London, England)|June 27, 2001
Cerebrospinal fluid response to structured treatment interruption after virological failureR W Price, E E Paxinos, R M Grant, et al.
AIDS (London, England)|August 16, 2001
Comparison of genotyping and phenotyping methods for determining susceptibility of HIV-1 to antiretroviral drugsA L Dunne, F M Mitchell, S K Coberly, et al.
The Journal of Infectious Diseases|July 7, 2000
Prevalence of mutations associated with reduced antiretroviral drug susceptibility among human immunodeficiency virus type 1 seroconverters in the United States, 1993-1998H Weinstock, R Respess, W Heneine, et al.
The Journal of Infectious Diseases|May 6, 1999
Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcomeS G Deeks, N S Hellmann, R M Grant, et al.
AIDS (London, England)|October 9, 2002
Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlatesJeannette M Whitcomb, Wei Huang, Kay Limoli, et al.
Antimicrobial Agents and Chemotherapy|September 16, 1998
Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(Phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adultsS G Deeks, P Barditch-Crovo, P S Lietman, et al.
Pageof 6

Showing results (21-30 of 56) with videos related to

Sort By:
Pageof 6
Archives of Biochemistry and Biophysics|October 1, 1989
Purification of homogeneity and amino acid sequence analysis of a receptor protein for interleukin 1A S Stern, Y C Pan, R S Hellmann, et al.
The Journal of Tropical Medicine and Hygiene|April 1, 1995
Single-dose ampicillin/sulbactam versus ceftriaxone as treatment for uncomplicated gonorrhoea in a Ugandan STD clinic population with a high prevalence of PPNG infectionN S Hellmann, P S Nsubuga, D J Baingana-Baingi, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|October 7, 2004
Effects of the G190A substitution of HIV reverse transcriptase on phenotypic susceptibility of patient isolates to delavirdineErik J Uhlmann, Pablo Tebas, Gregory A Storch, et al.
European Journal of Public Health|November 18, 2022
Labor force participation during COVID-19 and risk of depression: a Danish register studySophie S Hellmann, Sanne P Møller, Annette K Ersbøll, et al.
AIDS (London, England)|June 27, 2001
Cerebrospinal fluid response to structured treatment interruption after virological failureR W Price, E E Paxinos, R M Grant, et al.
AIDS (London, England)|August 16, 2001
Comparison of genotyping and phenotyping methods for determining susceptibility of HIV-1 to antiretroviral drugsA L Dunne, F M Mitchell, S K Coberly, et al.
The Journal of Infectious Diseases|July 7, 2000
Prevalence of mutations associated with reduced antiretroviral drug susceptibility among human immunodeficiency virus type 1 seroconverters in the United States, 1993-1998H Weinstock, R Respess, W Heneine, et al.
The Journal of Infectious Diseases|May 6, 1999
Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcomeS G Deeks, N S Hellmann, R M Grant, et al.
AIDS (London, England)|October 9, 2002
Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlatesJeannette M Whitcomb, Wei Huang, Kay Limoli, et al.
Antimicrobial Agents and Chemotherapy|September 16, 1998
Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(Phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adultsS G Deeks, P Barditch-Crovo, P S Lietman, et al.
Pageof 6